Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.67 |
| ▸ | SHBG | P04278 | 4/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.67 |
| ▸ | PGR | P06401 | 3/20 | 0.67 |
| ▸ | AR | P10275 | 3/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661927 | 1.00 | CYP3A4 (0.67) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR | |
| SCHEMBL3509140 | 1.00 | CYP3A4 (0.67) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR | |
| SCHEMBL5436459 | 1.00 | CYP3A4 (0.67) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR | |
| SCHEMBL8069 | 1.00 | CYP3A4 (0.67) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR | |
| SCHEMBL1457788 | 1.00 | CYP3A4 (0.67) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR | |
| SCHEMBL25333984 | 1.00 | CYP3A4 (0.67) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR | |
| SCHEMBL4747200 | 1.00 | CYP3A4 (0.67) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR | |
| SCHEMBL2724646 | 1.00 | CYP3A4 (0.67) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL3198033 | 0.99 | CYP3A4 (0.66) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR | |
| Bicarbonate SCHEMBL6684636 | 0.98 | CYP3A4 (0.65) | CYP3A4LMNASERPINA6SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313061-A1 | FORMULATIONS FOR PROLONGING GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022211810-A1 | FORMULATIONS FOR PROLONGING GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3265584-B1 | METHOD FOR PREDICTING CERVICAL SHORTENING AND PRETERM BIRTH | IMPERIAL COLLEGE SCI TECH & MEDICINE (GB) | 2021-06-02 | — | — | EP | claimed |
| WO-2025049529-A1 | RECOMBINANT HOST CELLS, POLYPEPTIDES AND PROCESSES FOR BIOSYNTHESIS OF HYDROCORTISONE | EPIMERON USA, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024259428-A2 | ESTROGENIC COMPOUNDS AND FORMULATIONS FOR GESTATION-RELATED COMPLICATIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4313061-A1 | FORMULATIONS FOR PROLONGING GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11590147-B2 | 17-hydroxyprogesterone ester-containing oral compositions and related methods | LIPOCINE INC. | 2023-02-28 | — | — | US | disclosed |
| WO-2022211810-A1 | FORMULATIONS FOR PROLONGING GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20210169900-A1 | 17-HYDROXYPROGESTERONE ESTER-CONTAINING ORAL COMPOSITIONS AND RELATED METHODS | LIPOCINE INC. (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3265584-B1 | METHOD FOR PREDICTING CERVICAL SHORTENING AND PRETERM BIRTH | IMPERIAL COLLEGE SCI TECH & MEDICINE (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20200140500-A1 | HIGH THROUGHPUT METHODS, PROTEIN INHIBITORS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-05-07 | — | — | US | disclosed |
| US-8946263-B2 | Compositions and methods for modulating circadian synchronization | MAX-PLANCK-GESELLCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2702052-A1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-20140031327-A1 | NON-SURGICAL METHOD OF TREATMENT FOR CATARACT | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014015024-A2 | NON-SURGICAL METHOD OF TREATMENT FOR CATARACT | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-01-23 | — | — | WO | disclosed |
| EP-2598150-A2 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | The Hospital For Sick Children (CA) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012018643-A2 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-09 | — | — | WO | disclosed |
| EP-0265350-B1 | NOVEL PLATINUM-STEROID COMPLEXES | Kidani, Yoshinori (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4690907-A | Capillary tube immunoassay | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 1987-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140500-A1 | HIGH THROUGHPUT METHODS, PROTEIN INHIBITORS, AND USES THEREOF | HSF1, HSP90B1, HSPH1 | CYP3A4 2481/4885LMNA 3845/4885SERPINA6 118/4885 |
| US-20140031327-A1 | NON-SURGICAL METHOD OF TREATMENT FOR CATARACT | CRYAB, CRYZ, CRYAA | CYP3A4 3432/4885LMNA 2786/4885SERPINA6 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.